The LATAM women hypoactive sexual desire disorder treatment market accounted for $131 million in 2019, and is expected to reach $170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.
Download Free Sample Copy:
https://www.alliedmarketresearch.com/request-sample/7952
List of key players profiled in the report:
- Aurobindo Pharma
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Mylan N.V.
- Novartis AG
- Palatin Technologies, Inc.
- Sprout Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila
- LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Amneal Pharmaceuticals
- Allergan plc
Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual disorder among women of all ages, however it is also one of the most challenging disorders to address. It is the most common type of sexual dysfunction that occurs in women. HSDD is mainly associated with hyper function inhibition and hypo functional excitation regulated by neuromodulators in the brain. In addition, several physical conditions are also related to HSDD, which include anxiety, depression, diabetes, urinary incontinence, and multiple sclerosis. Its treatment includes psychotherapy or pharmacotherapy. Psychotherapy utilizes cognitive behavioral therapy, which offers counseling sessions with a sex therapist, whereas pharmacotherapy comprises treatment with numerous drugs, namely buspirone, bremelanotide, bupropion, flibanserin, and others.
COVID-19 Impact Analysis on LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market
Lockdowns had an adverse impact on every type of business in Latin America. For instance, non-essential businesses such as retail business that operate with a physical location with access to public were closed. Furthermore, non-essential construction was also halted, recreational and entertainment businesses such as gyms, movie theaters, art centers, race tracks, salon, and public & private social clubs were also closed under the lock downs. However, essential businesses such as grocery stores, chemist stores, hospitals, veterinary hospitals remained functional during lockdowns. Furthermore, the impact of COVID-19 on LATAM women hypoactive sexual desire disorder treatment market was fairly negative, owing to fall in demand and supply of drugs used in treatment.
Furthermore, other factors that were responsible for a negative impact on the market included limited availability of medical care, shortage of healthcare staff, and rise in burden of COVID-19 related hospitalization. However, various governments are working toward ensuring undisrupted supply of drugs, which is expected to lead to a stabilization in the market overtime.
For Purchase Enquiry:
https://www.alliedmarketresearch.com/purchase-enquiry/7952
Key Findings Of The Study
- By treatment type, in terms of value, the bupropion segment dominated the market in 2019, and is anticipated to maintain its dominance throughout the forecast period
- By sales channel, the clinics segment is anticipated to grow with the highest CAGR throughout the forecast period.
- By treatment type, the bupropion segment accounted for more than half the share of the market in 2019.
- By country, Argentina is anticipated to grow at the highest rate during the analysis period.
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com